U.S. stock market midday update: IN8bio up 12.70%, trading volume increased, market sentiment is high

U.S. Stock Market Midday Update IN8bio, up 12.70%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Denaive Pharmaceuticals up 38.32%. Based on recent key news: On December 24, Sanofi announced it would acquire Denaive Pharmaceuticals for $15.5 per share in cash, with a total transaction value of approximately $2.2 billion. This news drove Denaive Pharmaceuticals' stock price up to $15.43, an increase of 38.59%. Sanofi stated that this acquisition would enhance its presence in the adult vaccine market. Source: Jinwu Financial News On December 24, Denaive Pharmaceuticals' stock price rose nearly 38% in pre-market trading, with Sanofi acquiring the company at a 39% premium. This transaction is expected to be completed in the first quarter of 2026, pushing the stock price to a three-year high. Source: Zhitong Finance On December 24, the acquisition news from Sanofi triggered short covering, significantly boosting Denaive Pharmaceuticals' stock price. Short positions accounted for 12.3% of the float, requiring about nine days to cover. Source: Biotech stock Dynavax Technologies Corp, vaccine industry consolidation accelerates, adult vaccination market expansion. AbbVie up 0.58%. Based on recent key news: On December 23, analyst ratings showed AbbVie was not included in the recommended buy list, despite its rating being moderate buy. This information may affect investor confidence, leading to stock price volatility. Source: MarketBeat On December 22, changes in the U.S. drug pricing system may impact AbbVie's market performance. With the implementation of the Most Favored Nation mechanism, drug price adjustments could affect the company's profitability. Source: FirstWord Pharma On December 22, analysts rated AbbVie as moderate buy but did not include it in the best buy list, which may affect market expectations. Source: MarketBeat, policy changes in the pharmaceutical industry affect market expectations. Agios Pharmaceuticals up 19.44%. Based on recent key news: On December 24, Agios Pharmaceuticals announced that its drug AQVESME received FDA approval for the treatment of adult α or β thalassemia anemia. This news drove the stock price up 19.44%. Source: Reuters On December 24, Agios Pharmaceuticals expects AQVESME to be launched in the U.S. by the end of January 2026, with an annual price of approximately $425,000. This pricing strategy further enhances market confidence in its commercial potential. Source: Zhitong Finance On December 24, analyst Greg Harrison raised Agios' target price from $32 to $34, reflecting market optimism about its expanded label commercial opportunities. Source: Bank of America Securities, recent policy support in the pharmaceutical industry leads to significant capital inflow Stocks Ranked Among the Top in Market Capitalization in the Industry Amgen rose by 0.47%. Based on recent news, On December 19, U.S. President Trump announced a new drug pricing agreement with nine global pharmaceutical giants, including Amgen, which will reduce the prices of certain drugs in the U.S. market by up to 70%. This move aims to alleviate the medical burden on American patients, promote drug price reform, and has boosted market confidence in Amgen, leading to an increase in its stock price. On December 19, Bernstein analyst Courtney Breen maintained a buy rating on Amgen and set a target price of $335. The analyst's positive assessment and high target price further boosted investor confidence, driving the stock price up. On December 18, Piper Sandler analyst David Amsellem also gave Amgen a buy rating. The positive evaluations and buy recommendations from multiple analysts enhanced market optimism regarding Amgen, contributing to the rise in its stock price. The pharmaceutical industry is performing well overall, supported by favorable policies